Fig. 2From: Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysisRisk of outcomes with different antidiabetic drug classes compared to placebo. a MACE (major adverse cardiovascular events). b Nonfatal myocardial infarction. c Nonfatal stroke. d Cardiovascular mortality. e All-cause mortality. f Hospitalisation for heart failure. g Renal composite outcomeBack to article page